Sponsor Pipeline

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
3
Recruiting
1
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-19 NCT07176689
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)		 date change Primary completion moved earlier: 2031-04-24 -> 2031-01-14
2026-07-19 NCT07176689
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)		 date change Completion moved earlier: 2031-04-24 -> 2031-01-14
Active Trials by Phase
Phase 4
1
Phase 2
2
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07176689 Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Desmoid Tumor Recruiting
Phase 2
NCT07170644 A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis… Desmoid Tumor Active, Not Recruiting
NCT03962543 MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1… Plexiform Neurofibroma Active, Not Recruiting
Phase 1
NCT06997276 Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib Healthy Recruiting
NCT06251310 SW-682 in Advanced Solid Tumors Advanced Solid Tumor Recruiting
Disease Areas
Mesothelioma (1)
Get alerts when SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free